



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Falnidamol

Chemical Properties

CAS No. :	196612-93-8
Formula:	C ₁₈ H ₁₉ ClFN ₇
Molecular Weight:	387.84
Appearance:	no data available
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year



Biological Description

Description	Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC ₅₀ of 3 nM. It displays >1000-fold lower potency against ErbB2 (IC ₅₀ =3.4 μM) and other related tyrosine kinases (IC ₅₀ >10 μM). Falnidamol is a pyrimido-pyrimidine compound and exhibits anti-cancer activity.
Targets(IC ₅₀)	EGFR
In vitro	Falnidamol displays > 1000-fold lower potency against ErbB2 (IC ₅₀ : 3.4 μM) and a range of other related tyrosine kinases (IC ₅₀ >10 μM) [1]. Falnidamol demonstrates antiproliferative activity in mitogenic assays performed with KB cells [2].
In vivo	Falnidamol (p.o.; 10 mg/kg/day; 16 days) completely suppressed tumor growth of human A431 xenografts with respective a T/C value of 15% after 2 weeks of treatment. Falnidamol (50 mg/kg/day for 2 weeks) results in dephosphorylation of the EGF receptor in A431 xenograft-bearing mice. With Falnidamol (p.o.; 10 mg/kg/day; 16 days), the C4h is 2222 nM and the C24h is 244 nM [2].
Animal Research	Animal Model: Five- to six-week-old athymic NMRI-nu/nu female mice (21-31 g) with A431, FaDu, or HN5 cells Dosage: 10 mg/kg Administration: p.o.; daily; 16 days Result: Completely suppressed tumor growth of human A431 xenografts with respective T/C values of 15 and 6% after 2 weeks of treatment [2].

Solubility Information

Solubility	DMSO: 28.8 mg/mL (74.3 mM), Sonication and heating to 60°C are recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5784 mL	12.8919 mL	25.7838 mL
5 mM	0.5157 mL	2.5784 mL	5.1568 mL
10 mM	0.2578 mL	1.2892 mL	2.5784 mL
50 mM	0.0516 mL	0.2578 mL	0.5157 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Dittrich Ch, et al. Phase I and pharmacokinetic study of BIBX 1382 B5, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481